Company intelligence / Profile preview

Alzheimer's Light

Cambridge, Massachusetts, United Statesalzheimers.gov ↗

Ownership: Private
Development stage: Other

Overview

Cognito Therapeutics has developed a non-invasive neuromodulation headset that uses synchronized light and sound stimulation to evoke gamma wave activity in the brain. In a Phase 2 trial, daily use of the device slowed cognitive and functional decline by over 80% compared to placebo, with additional evidence of preserved or increased white matter volume. No serious adverse events were reported. The pivotal Phase 3 trial is currently enrolling patients[1][2][3].

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation therapy (light and sound stimulation)
Industry: Therapeutic Medical Devices

Partnerships

Alzheimer’s Drug Discovery Foundation (investor/partner)Academic collaborations with MIT neuroscientists

Beyond the preview

Go deeper on Alzheimer's Light.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzheimer's Light.

Explore the full profile